Oligometastatic carcinoma prostate - An overview of the last decade.

IF 1.3 Q3 UROLOGY & NEPHROLOGY
Indian Journal of Urology Pub Date : 2023-07-01 Epub Date: 2023-06-30 DOI:10.4103/iju.iju_60_23
Milap J Shah, Aditya Prakash Sharma, B M Zeeshan Hameed, Ravi Jain, Abhijit Patil, Naganathan Karthickeyan, Abhishek Singh
{"title":"Oligometastatic carcinoma prostate - An overview of the last decade.","authors":"Milap J Shah,&nbsp;Aditya Prakash Sharma,&nbsp;B M Zeeshan Hameed,&nbsp;Ravi Jain,&nbsp;Abhijit Patil,&nbsp;Naganathan Karthickeyan,&nbsp;Abhishek Singh","doi":"10.4103/iju.iju_60_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Oligometastatic prostate cancer (OMPC) has gained profound interest lately due to its different tumor biology and our ability to use multimodality therapy for cure or prolonged survival. Selecting the appropriate patient for treatment has become the aim of treating urologists, medical oncologists, and radiation oncologists. Through this review, we try to highlight the management of OMPC in light of recent literature.</p><p><strong>Methods: </strong>Literature search was performed on Pubmed, Scopus and Embase using keywords \"Oligometastatic\", \" Prostate Cancer\" using operators such as \"And\" & \"Or\". Relevant articles were screened and all the latest articles on this emerging entity were included in this review.</p><p><strong>Results: </strong>All trials relevant to oligometastatic prostate cancer defining the role of surgery, radiotherapy and systemic therapy were included and appropriate inferences were drawn. Relevant studies were compiled in tabular form for this article.</p><p><strong>Conclusion: </strong>The current standard of care of management for OMPC remains systemic therapy on the lines of hormone-sensitive metastatic prostate cancer. The evolving role of surgery, and radiotherapy along with systemic therapy is highlighted in this article.</p>","PeriodicalId":47352,"journal":{"name":"Indian Journal of Urology","volume":"39 3","pages":"195-201"},"PeriodicalIF":1.3000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/a2/IJU-39-195.PMC10419768.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/iju.iju_60_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Introduction: Oligometastatic prostate cancer (OMPC) has gained profound interest lately due to its different tumor biology and our ability to use multimodality therapy for cure or prolonged survival. Selecting the appropriate patient for treatment has become the aim of treating urologists, medical oncologists, and radiation oncologists. Through this review, we try to highlight the management of OMPC in light of recent literature.

Methods: Literature search was performed on Pubmed, Scopus and Embase using keywords "Oligometastatic", " Prostate Cancer" using operators such as "And" & "Or". Relevant articles were screened and all the latest articles on this emerging entity were included in this review.

Results: All trials relevant to oligometastatic prostate cancer defining the role of surgery, radiotherapy and systemic therapy were included and appropriate inferences were drawn. Relevant studies were compiled in tabular form for this article.

Conclusion: The current standard of care of management for OMPC remains systemic therapy on the lines of hormone-sensitive metastatic prostate cancer. The evolving role of surgery, and radiotherapy along with systemic therapy is highlighted in this article.

前列腺低转移癌——过去十年的综述。
简介:由于其不同的肿瘤生物学以及我们使用多模式治疗治愈或延长生存期的能力,少转移性癌症(OMPC)最近引起了人们的极大兴趣。选择合适的患者进行治疗已成为泌尿科医生、医学肿瘤学家和放射肿瘤学家治疗的目标。通过这篇综述,我们试图根据最近的文献来强调OMPC的管理。方法:在Pubmed、Scopus和Embase上使用“寡转移”、“前列腺癌症”等关键字,使用“and”和“Or”等运算符进行文献检索。对相关文章进行了筛选,所有关于这一新兴实体的最新文章都包含在本次审查中。结果:纳入了所有与少转移性前列腺癌症相关的试验,确定了手术、放疗和全身治疗的作用,并得出了适当的推论。本文以表格形式汇编了相关研究。结论:目前OMPC的治疗标准仍然是激素敏感性转移性前列腺癌症的系统治疗。这篇文章强调了手术、放疗和全身治疗的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Indian Journal of Urology
Indian Journal of Urology UROLOGY & NEPHROLOGY-
CiteScore
1.90
自引率
0.00%
发文量
62
审稿时长
33 weeks
期刊介绍: Indian Journal of Urology-IJU (ISSN 0970-1591) is official publication of the Urological Society of India. The journal is published Quarterly. Bibliographic listings: The journal is indexed with Abstracts on Hygiene and Communicable Diseases, CAB Abstracts, Caspur, DOAJ, EBSCO Publishing’s Electronic Databases, Excerpta Medica / EMBASE, Expanded Academic ASAP, Genamics JournalSeek, Global Health, Google Scholar, Health & Wellness Research Center, Health Reference Center Academic, Hinari, Index Copernicus, IndMed, OpenJGate, PubMed, Pubmed Central, Scimago Journal Ranking, SCOLOAR, SCOPUS, SIIC databases, SNEMB, Tropical Diseases Bulletin, Ulrich’s International Periodical Directory
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信